Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3871801 in Moderately-to-Severely Active Rheumatoid Arthritis
2022-502994-40-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing LY3871801 with Placebo (2 arms). Primary endpoints: Change from Baseline in DAS28-hsCRP (Phase 2a) and ACR50 response rate (Phase 2b). Started Aug 2023; status: completed.
02
Drugs
ocadusertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-502994-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502994-40-00.